VistaPath Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Later Stage VC
- Investors
-
9
VistaPath General Information
Description
Developer of medical technologies designed to modernize pathology labs using machine augmentation. The company's pathology system photographs and uses artificial intelligence to automate the process of inspecting, describing, inking, and measuring tissues to be processed for diagnosis, enabling pathologists to prepare samples for diagnosis automatically and reduce errors involved with the process.
Contact Information
Website
www.vistapath.aiCorporate Office
- 1166 Massachusetts Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- 1166 Massachusetts Avenue
- Cambridge, MA 02138
- United States
VistaPath Timeline
VistaPath Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 21-Jun-2024 | Completed | Generating Revenue | |||
| 3. Seed Round | 07-Jul-2023 | Completed | Generating Revenue | |||
| 2. Seed Round | 21-Jun-2022 | $7.42M | $7.42M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 20-Feb-2018 | Completed | Startup |
VistaPath Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 2A | ||||||||
| Seed-6 | ||||||||
| Seed-5 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 263,511 | $0.000100 | $1.15 | $1.15 | 1x | $1.15 | 1.17% | |
| Seed-1 | 2,769,503 | $0.000100 | $1.44 | $1.44 | 1x | $1.44 | 12.33% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
VistaPath Patents
VistaPath Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3818378-A2 | Apparatus and methods for processing and cataloging of samples | Active | 05-Jul-2018 | ||
| US-10684295-B2 | Apparatus and methods for processing and cataloging of samples | Active | 05-Jul-2018 | ||
| US-20200011887-A1 | Apparatus and methods for processing and cataloging of samples | Active | 05-Jul-2018 | ||
| US-20200233000-A1 | Apparatus and methods for processing and cataloging of samples | Inactive | 05-Jul-2018 | ||
| WO-2020009865-A2 | Apparatus and methods for processing and cataloging of samples | Inactive | 05-Jul-2018 | G01N35/00732 |
VistaPath Signals
VistaPath Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ValueStream Ventures | Venture Capital | Minority | ||
| Scribble Ventures | Venture Capital | Minority | ||
| Spero Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| First Star Ventures | Venture Capital | Minority |
VistaPath FAQs
-
When was VistaPath founded?
VistaPath was founded in 2017.
-
Where is VistaPath headquartered?
VistaPath is headquartered in Cambridge, MA.
-
What is the size of VistaPath?
VistaPath has 14 total employees.
-
What industry is VistaPath in?
VistaPath’s primary industry is Other Devices and Supplies.
-
Is VistaPath a private or public company?
VistaPath is a Private company.
-
What is VistaPath’s current revenue?
The current revenue for VistaPath is .
-
How much funding has VistaPath raised over time?
VistaPath has raised $12.9M.
-
Who are VistaPath’s investors?
ValueStream Ventures, Scribble Ventures, Spero Ventures, , and First Star Ventures are 5 of 9 investors who have invested in VistaPath.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process